Deborah Y. Evans

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

John F. DiJoseph, Maureen Dougher, Douglas Armellino et al. · Leukemia · 2007 · 134 citations

Inotuzumab Ozogamicin, Lymphoid Neoplasia, Hematological Malignancy +9

Emetic, central nervous system and pulmonary activities of rolipram in the dog

Richard J. Heaslip, Deborah Y. Evans · European Journal of Pharmacology · 1995 · 96 citations

Veterinary Physiology, Physiology, Pulmonary Activities +7

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

Marc Damelin, Kenneth G. Geles, Maximillian T. Follettie et al. · Cancer Research · 2011 · 79 citations

Cancer Immunosurveillance, Tumor Heterogeneity, Tumor-initiating Cells +14

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

John F. DiJoseph, Maureen Dougher, Deborah Y. Evans et al. · Cancer Chemotherapy and Pharmacology · 2010 · 46 citations

Inotuzumab Ozogamicin, Oncology, Medicine +11

Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.

Richard J. Heaslip, Laura Lombardo, J. M. Golankiewicz et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 31 citations